nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—COMT—Conjugated Estrogens—osteoporosis	0.702	1	CbGbCtD
Methyldopa—DDC—Parkinsons Disease Pathway—PARK7—osteoporosis	0.00206	0.102	CbGpPWpGaD
Methyldopa—DDC—Dopaminergic Neurogenesis—WNT1—osteoporosis	0.00134	0.0667	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—ID4—osteoporosis	0.00111	0.0552	CbGpPWpGaD
Methyldopa—Myalgia—Raloxifene—osteoporosis	0.000756	0.00272	CcSEcCtD
Methyldopa—Arthralgia—Raloxifene—osteoporosis	0.000756	0.00272	CcSEcCtD
Methyldopa—Angiopathy—Risedronate—osteoporosis	0.000755	0.00272	CcSEcCtD
Methyldopa—Agranulocytosis—Zoledronate—osteoporosis	0.000751	0.0027	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.000751	0.0027	CcSEcCtD
Methyldopa—Mediastinal disorder—Risedronate—osteoporosis	0.00075	0.0027	CcSEcCtD
Methyldopa—Arthralgia—Ibandronate—osteoporosis	0.000749	0.00269	CcSEcCtD
Methyldopa—Myalgia—Ibandronate—osteoporosis	0.000749	0.00269	CcSEcCtD
Methyldopa—Oedema—Estropipate—osteoporosis	0.000748	0.00269	CcSEcCtD
Methyldopa—Mental disorder—Ethinyl Estradiol—osteoporosis	0.000748	0.00269	CcSEcCtD
Methyldopa—Infection—Estropipate—osteoporosis	0.000744	0.00267	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.000743	0.00267	CcSEcCtD
Methyldopa—Liver function test abnormal—Estradiol—osteoporosis	0.000743	0.00267	CcSEcCtD
Methyldopa—Constipation—Etidronic acid—osteoporosis	0.00074	0.00266	CcSEcCtD
Methyldopa—Bradycardia—Zoledronate—osteoporosis	0.000736	0.00265	CcSEcCtD
Methyldopa—Cardiac disorder—Pamidronate—osteoporosis	0.000734	0.00264	CcSEcCtD
Methyldopa—Nervous system disorder—Estropipate—osteoporosis	0.000734	0.00264	CcSEcCtD
Methyldopa—Hepatobiliary disease—Conjugated Estrogens—osteoporosis	0.000733	0.00264	CcSEcCtD
Methyldopa—Myalgia—Calcitriol—osteoporosis	0.000733	0.00264	CcSEcCtD
Methyldopa—Infection—Alendronate—osteoporosis	0.000732	0.00263	CcSEcCtD
Methyldopa—Mental disorder—Risedronate—osteoporosis	0.000729	0.00262	CcSEcCtD
Methyldopa—Breast disorder—Estradiol—osteoporosis	0.000728	0.00262	CcSEcCtD
Methyldopa—Skin disorder—Estropipate—osteoporosis	0.000727	0.00261	CcSEcCtD
Methyldopa—Infection—Raloxifene—osteoporosis	0.00072	0.00259	CcSEcCtD
Methyldopa—Angiopathy—Pamidronate—osteoporosis	0.000718	0.00258	CcSEcCtD
Methyldopa—Flatulence—Risedronate—osteoporosis	0.000714	0.00257	CcSEcCtD
Methyldopa—Mediastinal disorder—Pamidronate—osteoporosis	0.000713	0.00256	CcSEcCtD
Methyldopa—Infection—Ibandronate—osteoporosis	0.000713	0.00256	CcSEcCtD
Methyldopa—Nervous system disorder—Raloxifene—osteoporosis	0.000711	0.00256	CcSEcCtD
Methyldopa—Connective tissue disorder—Zoledronate—osteoporosis	0.00071	0.00255	CcSEcCtD
Methyldopa—Thrombocytopenia—Raloxifene—osteoporosis	0.00071	0.00255	CcSEcCtD
Methyldopa—Skin disorder—Raloxifene—osteoporosis	0.000704	0.00253	CcSEcCtD
Methyldopa—Nervous system disorder—Ibandronate—osteoporosis	0.000704	0.00253	CcSEcCtD
Methyldopa—Abdominal distension—Estradiol—osteoporosis	0.000701	0.00252	CcSEcCtD
Methyldopa—Skin disorder—Ibandronate—osteoporosis	0.000697	0.00251	CcSEcCtD
Methyldopa—Nausea—Ergocalciferol—osteoporosis	0.000691	0.00249	CcSEcCtD
Methyldopa—Skin disorder—Calcitriol—osteoporosis	0.000682	0.00245	CcSEcCtD
Methyldopa—Pancreatitis—Estradiol—osteoporosis	0.000682	0.00245	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Estropipate—osteoporosis	0.000682	0.00245	CcSEcCtD
Methyldopa—Paraesthesia—Estropipate—osteoporosis	0.000672	0.00242	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Alendronate—osteoporosis	0.000672	0.00241	CcSEcCtD
Methyldopa—Cardiac disorder—Zoledronate—osteoporosis	0.000671	0.00241	CcSEcCtD
Methyldopa—DDC—Tryptophan metabolism—CYP19A1—osteoporosis	0.000661	0.0328	CbGpPWpGaD
Methyldopa—Musculoskeletal discomfort—Raloxifene—osteoporosis	0.00066	0.00237	CcSEcCtD
Methyldopa—Angiopathy—Zoledronate—osteoporosis	0.000656	0.00236	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Ibandronate—osteoporosis	0.000654	0.00235	CcSEcCtD
Methyldopa—Mediastinal disorder—Zoledronate—osteoporosis	0.000651	0.00234	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Estropipate—osteoporosis	0.000646	0.00232	CcSEcCtD
Methyldopa—Cardiac disorder—Conjugated Estrogens—osteoporosis	0.000646	0.00232	CcSEcCtD
Methyldopa—Paraesthesia—Ibandronate—osteoporosis	0.000644	0.00232	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Calcitriol—osteoporosis	0.00064	0.0023	CcSEcCtD
Methyldopa—Constipation—Estropipate—osteoporosis	0.00064	0.0023	CcSEcCtD
Methyldopa—Hypersensitivity—Etidronic acid—osteoporosis	0.000637	0.00229	CcSEcCtD
Methyldopa—Weight increased—Estradiol—osteoporosis	0.000633	0.00228	CcSEcCtD
Methyldopa—Mental disorder—Zoledronate—osteoporosis	0.000633	0.00228	CcSEcCtD
Methyldopa—Angiopathy—Conjugated Estrogens—osteoporosis	0.000632	0.00227	CcSEcCtD
Methyldopa—Constipation—Alendronate—osteoporosis	0.00063	0.00227	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000628	0.00226	CcSEcCtD
Methyldopa—Mediastinal disorder—Conjugated Estrogens—osteoporosis	0.000627	0.00226	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000626	0.00225	CcSEcCtD
Methyldopa—Infestation—Estradiol—osteoporosis	0.000621	0.00223	CcSEcCtD
Methyldopa—Infestation NOS—Estradiol—osteoporosis	0.000621	0.00223	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Ibandronate—osteoporosis	0.00062	0.00223	CcSEcCtD
Methyldopa—Myalgia—Risedronate—osteoporosis	0.000617	0.00222	CcSEcCtD
Methyldopa—Arthralgia—Risedronate—osteoporosis	0.000617	0.00222	CcSEcCtD
Methyldopa—Leukopenia—Pamidronate—osteoporosis	0.000617	0.00222	CcSEcCtD
Methyldopa—Constipation—Ibandronate—osteoporosis	0.000614	0.00221	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000613	0.0022	CcSEcCtD
Methyldopa—Mental disorder—Conjugated Estrogens—osteoporosis	0.00061	0.00219	CcSEcCtD
Methyldopa—Oedema—Ethinyl Estradiol—osteoporosis	0.000607	0.00218	CcSEcCtD
Methyldopa—Jaundice—Estradiol—osteoporosis	0.000605	0.00217	CcSEcCtD
Methyldopa—Infection—Ethinyl Estradiol—osteoporosis	0.000603	0.00217	CcSEcCtD
Methyldopa—Constipation—Calcitriol—osteoporosis	0.000601	0.00216	CcSEcCtD
Methyldopa—Flatulence—Conjugated Estrogens—osteoporosis	0.000597	0.00215	CcSEcCtD
Methyldopa—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000595	0.00214	CcSEcCtD
Methyldopa—Diarrhoea—Etidronic acid—osteoporosis	0.000592	0.00213	CcSEcCtD
Methyldopa—Body temperature increased—Estropipate—osteoporosis	0.000592	0.00213	CcSEcCtD
Methyldopa—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000589	0.00212	CcSEcCtD
Methyldopa—Infection—Risedronate—osteoporosis	0.000588	0.00211	CcSEcCtD
Methyldopa—Hepatobiliary disease—Estradiol—osteoporosis	0.000587	0.00211	CcSEcCtD
Methyldopa—Myalgia—Pamidronate—osteoporosis	0.000587	0.00211	CcSEcCtD
Methyldopa—Arthralgia—Pamidronate—osteoporosis	0.000587	0.00211	CcSEcCtD
Methyldopa—Body temperature increased—Alendronate—osteoporosis	0.000583	0.0021	CcSEcCtD
Methyldopa—Nervous system disorder—Risedronate—osteoporosis	0.00058	0.00209	CcSEcCtD
Methyldopa—Skin disorder—Risedronate—osteoporosis	0.000574	0.00207	CcSEcCtD
Methyldopa—Body temperature increased—Raloxifene—osteoporosis	0.000573	0.00206	CcSEcCtD
Methyldopa—Body temperature increased—Ibandronate—osteoporosis	0.000567	0.00204	CcSEcCtD
Methyldopa—Leukopenia—Zoledronate—osteoporosis	0.000563	0.00203	CcSEcCtD
Methyldopa—Oedema—Pamidronate—osteoporosis	0.000562	0.00202	CcSEcCtD
Methyldopa—Infection—Pamidronate—osteoporosis	0.000559	0.00201	CcSEcCtD
Methyldopa—Hepatitis—Estradiol—osteoporosis	0.000557	0.002	CcSEcCtD
Methyldopa—Body temperature increased—Calcitriol—osteoporosis	0.000555	0.002	CcSEcCtD
Methyldopa—Hypersensitivity—Estropipate—osteoporosis	0.000551	0.00198	CcSEcCtD
Methyldopa—Nervous system disorder—Pamidronate—osteoporosis	0.000551	0.00198	CcSEcCtD
Methyldopa—Thrombocytopenia—Pamidronate—osteoporosis	0.00055	0.00198	CcSEcCtD
Methyldopa—Vomiting—Etidronic acid—osteoporosis	0.00055	0.00198	CcSEcCtD
Methyldopa—Connective tissue disorder—Estradiol—osteoporosis	0.000547	0.00197	CcSEcCtD
Methyldopa—Rash—Etidronic acid—osteoporosis	0.000545	0.00196	CcSEcCtD
Methyldopa—Dermatitis—Etidronic acid—osteoporosis	0.000545	0.00196	CcSEcCtD
Methyldopa—Hypersensitivity—Alendronate—osteoporosis	0.000543	0.00195	CcSEcCtD
Methyldopa—Headache—Etidronic acid—osteoporosis	0.000542	0.00195	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000539	0.00194	CcSEcCtD
Methyldopa—Asthenia—Estropipate—osteoporosis	0.000537	0.00193	CcSEcCtD
Methyldopa—Arthralgia—Zoledronate—osteoporosis	0.000536	0.00193	CcSEcCtD
Methyldopa—Myalgia—Zoledronate—osteoporosis	0.000536	0.00193	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000532	0.00191	CcSEcCtD
Methyldopa—Paraesthesia—Risedronate—osteoporosis	0.000531	0.00191	CcSEcCtD
Methyldopa—Asthenia—Alendronate—osteoporosis	0.000529	0.0019	CcSEcCtD
Methyldopa—Hypersensitivity—Ibandronate—osteoporosis	0.000529	0.0019	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000524	0.00188	CcSEcCtD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—TLN1—osteoporosis	0.000521	0.0259	CbGpPWpGaD
Methyldopa—Constipation—Ethinyl Estradiol—osteoporosis	0.000519	0.00187	CcSEcCtD
Methyldopa—Hypersensitivity—Calcitriol—osteoporosis	0.000518	0.00186	CcSEcCtD
Methyldopa—Cardiac disorder—Estradiol—osteoporosis	0.000517	0.00186	CcSEcCtD
Methyldopa—Arthralgia—Conjugated Estrogens—osteoporosis	0.000516	0.00185	CcSEcCtD
Methyldopa—Myalgia—Conjugated Estrogens—osteoporosis	0.000516	0.00185	CcSEcCtD
Methyldopa—Asthenia—Ibandronate—osteoporosis	0.000515	0.00185	CcSEcCtD
Methyldopa—Nausea—Etidronic acid—osteoporosis	0.000514	0.00185	CcSEcCtD
Methyldopa—Oedema—Zoledronate—osteoporosis	0.000514	0.00185	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000512	0.00184	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000512	0.00184	CcSEcCtD
Methyldopa—Diarrhoea—Estropipate—osteoporosis	0.000512	0.00184	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Risedronate—osteoporosis	0.000511	0.00184	CcSEcCtD
Methyldopa—Infection—Zoledronate—osteoporosis	0.00051	0.00183	CcSEcCtD
Methyldopa—Constipation—Risedronate—osteoporosis	0.000506	0.00182	CcSEcCtD
Methyldopa—Angiopathy—Estradiol—osteoporosis	0.000505	0.00182	CcSEcCtD
Methyldopa—Paraesthesia—Pamidronate—osteoporosis	0.000505	0.00182	CcSEcCtD
Methyldopa—Diarrhoea—Alendronate—osteoporosis	0.000504	0.00181	CcSEcCtD
Methyldopa—Asthenia—Calcitriol—osteoporosis	0.000504	0.00181	CcSEcCtD
Methyldopa—Nervous system disorder—Zoledronate—osteoporosis	0.000504	0.00181	CcSEcCtD
Methyldopa—Thrombocytopenia—Zoledronate—osteoporosis	0.000503	0.00181	CcSEcCtD
Methyldopa—Mediastinal disorder—Estradiol—osteoporosis	0.000502	0.00181	CcSEcCtD
Methyldopa—Skin disorder—Zoledronate—osteoporosis	0.000499	0.00179	CcSEcCtD
Methyldopa—Diarrhoea—Raloxifene—osteoporosis	0.000496	0.00178	CcSEcCtD
Methyldopa—Dizziness—Estropipate—osteoporosis	0.000495	0.00178	CcSEcCtD
Methyldopa—Oedema—Conjugated Estrogens—osteoporosis	0.000495	0.00178	CcSEcCtD
Methyldopa—Infection—Conjugated Estrogens—osteoporosis	0.000491	0.00177	CcSEcCtD
Methyldopa—Diarrhoea—Ibandronate—osteoporosis	0.000491	0.00177	CcSEcCtD
Methyldopa—Mental disorder—Estradiol—osteoporosis	0.000488	0.00175	CcSEcCtD
Methyldopa—Dizziness—Alendronate—osteoporosis	0.000487	0.00175	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000485	0.00175	CcSEcCtD
Methyldopa—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000485	0.00174	CcSEcCtD
Methyldopa—Constipation—Pamidronate—osteoporosis	0.000481	0.00173	CcSEcCtD
Methyldopa—Diarrhoea—Calcitriol—osteoporosis	0.000481	0.00173	CcSEcCtD
Methyldopa—Skin disorder—Conjugated Estrogens—osteoporosis	0.00048	0.00173	CcSEcCtD
Methyldopa—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.00048	0.00172	CcSEcCtD
Methyldopa—Dizziness—Raloxifene—osteoporosis	0.000479	0.00172	CcSEcCtD
Methyldopa—Flatulence—Estradiol—osteoporosis	0.000478	0.00172	CcSEcCtD
Methyldopa—Vomiting—Estropipate—osteoporosis	0.000476	0.00171	CcSEcCtD
Methyldopa—Dizziness—Ibandronate—osteoporosis	0.000475	0.00171	CcSEcCtD
Methyldopa—Rash—Estropipate—osteoporosis	0.000472	0.0017	CcSEcCtD
Methyldopa—Dermatitis—Estropipate—osteoporosis	0.000471	0.0017	CcSEcCtD
Methyldopa—Headache—Estropipate—osteoporosis	0.000469	0.00169	CcSEcCtD
Methyldopa—Vomiting—Alendronate—osteoporosis	0.000469	0.00169	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000468	0.00168	CcSEcCtD
Methyldopa—Body temperature increased—Risedronate—osteoporosis	0.000468	0.00168	CcSEcCtD
Methyldopa—Rash—Alendronate—osteoporosis	0.000465	0.00167	CcSEcCtD
Methyldopa—Dermatitis—Alendronate—osteoporosis	0.000464	0.00167	CcSEcCtD
Methyldopa—Headache—Alendronate—osteoporosis	0.000462	0.00166	CcSEcCtD
Methyldopa—Paraesthesia—Zoledronate—osteoporosis	0.000461	0.00166	CcSEcCtD
Methyldopa—Vomiting—Raloxifene—osteoporosis	0.000461	0.00166	CcSEcCtD
Methyldopa—Rash—Raloxifene—osteoporosis	0.000457	0.00164	CcSEcCtD
Methyldopa—Dermatitis—Raloxifene—osteoporosis	0.000457	0.00164	CcSEcCtD
Methyldopa—Vomiting—Ibandronate—osteoporosis	0.000456	0.00164	CcSEcCtD
Methyldopa—Headache—Raloxifene—osteoporosis	0.000454	0.00163	CcSEcCtD
Methyldopa—Rash—Ibandronate—osteoporosis	0.000453	0.00163	CcSEcCtD
Methyldopa—Dermatitis—Ibandronate—osteoporosis	0.000452	0.00163	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000451	0.00162	CcSEcCtD
Methyldopa—Headache—Ibandronate—osteoporosis	0.00045	0.00162	CcSEcCtD
Methyldopa—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000447	0.00161	CcSEcCtD
Methyldopa—Vomiting—Calcitriol—osteoporosis	0.000447	0.00161	CcSEcCtD
Methyldopa—Nausea—Estropipate—osteoporosis	0.000445	0.0016	CcSEcCtD
Methyldopa—Body temperature increased—Pamidronate—osteoporosis	0.000444	0.0016	CcSEcCtD
Methyldopa—Paraesthesia—Conjugated Estrogens—osteoporosis	0.000444	0.0016	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000443	0.00159	CcSEcCtD
Methyldopa—Rash—Calcitriol—osteoporosis	0.000443	0.00159	CcSEcCtD
Methyldopa—Dermatitis—Calcitriol—osteoporosis	0.000443	0.00159	CcSEcCtD
Methyldopa—Headache—Calcitriol—osteoporosis	0.00044	0.00158	CcSEcCtD
Methyldopa—Constipation—Zoledronate—osteoporosis	0.000439	0.00158	CcSEcCtD
Methyldopa—Nausea—Alendronate—osteoporosis	0.000438	0.00157	CcSEcCtD
Methyldopa—Hypersensitivity—Risedronate—osteoporosis	0.000436	0.00157	CcSEcCtD
Methyldopa—Asthenia—Ethinyl Estradiol—osteoporosis	0.000435	0.00156	CcSEcCtD
Methyldopa—Nausea—Raloxifene—osteoporosis	0.000431	0.00155	CcSEcCtD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—RAP1A—osteoporosis	0.00043	0.0213	CbGpPWpGaD
Methyldopa—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000427	0.00154	CcSEcCtD
Methyldopa—Nausea—Ibandronate—osteoporosis	0.000426	0.00153	CcSEcCtD
Methyldopa—Asthenia—Risedronate—osteoporosis	0.000424	0.00153	CcSEcCtD
Methyldopa—Constipation—Conjugated Estrogens—osteoporosis	0.000423	0.00152	CcSEcCtD
Methyldopa—Nausea—Calcitriol—osteoporosis	0.000417	0.0015	CcSEcCtD
Methyldopa—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000415	0.00149	CcSEcCtD
Methyldopa—Hypersensitivity—Pamidronate—osteoporosis	0.000414	0.00149	CcSEcCtD
Methyldopa—Myalgia—Estradiol—osteoporosis	0.000413	0.00148	CcSEcCtD
Methyldopa—Arthralgia—Estradiol—osteoporosis	0.000413	0.00148	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.00041	0.00147	CcSEcCtD
Methyldopa—Body temperature increased—Zoledronate—osteoporosis	0.000406	0.00146	CcSEcCtD
Methyldopa—Diarrhoea—Risedronate—osteoporosis	0.000405	0.00146	CcSEcCtD
Methyldopa—Asthenia—Pamidronate—osteoporosis	0.000403	0.00145	CcSEcCtD
Methyldopa—Dizziness—Ethinyl Estradiol—osteoporosis	0.000401	0.00144	CcSEcCtD
Methyldopa—Oedema—Estradiol—osteoporosis	0.000396	0.00142	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—GAPDH—osteoporosis	0.000395	0.0196	CbGpPWpGaD
Methyldopa—Infection—Estradiol—osteoporosis	0.000393	0.00141	CcSEcCtD
Methyldopa—Dizziness—Risedronate—osteoporosis	0.000391	0.00141	CcSEcCtD
Methyldopa—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000391	0.00141	CcSEcCtD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—FGA—osteoporosis	0.00039	0.0193	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—CYP27A1—osteoporosis	0.000389	0.0193	CbGpPWpGaD
Methyldopa—Nervous system disorder—Estradiol—osteoporosis	0.000388	0.0014	CcSEcCtD
Methyldopa—Vomiting—Ethinyl Estradiol—osteoporosis	0.000386	0.00139	CcSEcCtD
Methyldopa—Diarrhoea—Pamidronate—osteoporosis	0.000385	0.00138	CcSEcCtD
Methyldopa—Skin disorder—Estradiol—osteoporosis	0.000384	0.00138	CcSEcCtD
Methyldopa—COMT—Metapathway biotransformation—CYP27A1—osteoporosis	0.000384	0.0191	CbGpPWpGaD
Methyldopa—Rash—Ethinyl Estradiol—osteoporosis	0.000382	0.00138	CcSEcCtD
Methyldopa—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000382	0.00137	CcSEcCtD
Methyldopa—Headache—Ethinyl Estradiol—osteoporosis	0.00038	0.00137	CcSEcCtD
Methyldopa—Hypersensitivity—Zoledronate—osteoporosis	0.000378	0.00136	CcSEcCtD
Methyldopa—Vomiting—Risedronate—osteoporosis	0.000376	0.00135	CcSEcCtD
Methyldopa—Rash—Risedronate—osteoporosis	0.000373	0.00134	CcSEcCtD
Methyldopa—Dermatitis—Risedronate—osteoporosis	0.000373	0.00134	CcSEcCtD
Methyldopa—Dizziness—Pamidronate—osteoporosis	0.000372	0.00134	CcSEcCtD
Methyldopa—Headache—Risedronate—osteoporosis	0.000371	0.00133	CcSEcCtD
Methyldopa—Asthenia—Zoledronate—osteoporosis	0.000368	0.00132	CcSEcCtD
Methyldopa—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000364	0.00131	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Estradiol—osteoporosis	0.000361	0.0013	CcSEcCtD
Methyldopa—Nausea—Ethinyl Estradiol—osteoporosis	0.00036	0.0013	CcSEcCtD
Methyldopa—Vomiting—Pamidronate—osteoporosis	0.000357	0.00129	CcSEcCtD
Methyldopa—Paraesthesia—Estradiol—osteoporosis	0.000355	0.00128	CcSEcCtD
Methyldopa—Asthenia—Conjugated Estrogens—osteoporosis	0.000355	0.00128	CcSEcCtD
Methyldopa—Rash—Pamidronate—osteoporosis	0.000355	0.00127	CcSEcCtD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—FGB—osteoporosis	0.000354	0.0176	CbGpPWpGaD
Methyldopa—Dermatitis—Pamidronate—osteoporosis	0.000354	0.00127	CcSEcCtD
Methyldopa—Headache—Pamidronate—osteoporosis	0.000352	0.00127	CcSEcCtD
Methyldopa—Diarrhoea—Zoledronate—osteoporosis	0.000351	0.00126	CcSEcCtD
Methyldopa—Nausea—Risedronate—osteoporosis	0.000351	0.00126	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Estradiol—osteoporosis	0.000342	0.00123	CcSEcCtD
Methyldopa—Dizziness—Zoledronate—osteoporosis	0.00034	0.00122	CcSEcCtD
Methyldopa—Constipation—Estradiol—osteoporosis	0.000338	0.00122	CcSEcCtD
Methyldopa—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000338	0.00122	CcSEcCtD
Methyldopa—Nausea—Pamidronate—osteoporosis	0.000334	0.0012	CcSEcCtD
Methyldopa—Dizziness—Conjugated Estrogens—osteoporosis	0.000327	0.00118	CcSEcCtD
Methyldopa—Vomiting—Zoledronate—osteoporosis	0.000327	0.00117	CcSEcCtD
Methyldopa—Rash—Zoledronate—osteoporosis	0.000324	0.00116	CcSEcCtD
Methyldopa—Dermatitis—Zoledronate—osteoporosis	0.000324	0.00116	CcSEcCtD
Methyldopa—DDC—Dopaminergic Neurogenesis—TGFB1—osteoporosis	0.000322	0.016	CbGpPWpGaD
Methyldopa—Headache—Zoledronate—osteoporosis	0.000322	0.00116	CcSEcCtD
Methyldopa—Vomiting—Conjugated Estrogens—osteoporosis	0.000314	0.00113	CcSEcCtD
Methyldopa—Body temperature increased—Estradiol—osteoporosis	0.000313	0.00112	CcSEcCtD
Methyldopa—Rash—Conjugated Estrogens—osteoporosis	0.000312	0.00112	CcSEcCtD
Methyldopa—Dermatitis—Conjugated Estrogens—osteoporosis	0.000312	0.00112	CcSEcCtD
Methyldopa—Headache—Conjugated Estrogens—osteoporosis	0.00031	0.00111	CcSEcCtD
Methyldopa—Nausea—Zoledronate—osteoporosis	0.000305	0.0011	CcSEcCtD
Methyldopa—Nausea—Conjugated Estrogens—osteoporosis	0.000294	0.00106	CcSEcCtD
Methyldopa—Hypersensitivity—Estradiol—osteoporosis	0.000292	0.00105	CcSEcCtD
Methyldopa—Asthenia—Estradiol—osteoporosis	0.000284	0.00102	CcSEcCtD
Methyldopa—ADRA2A—Adrenaline,noradrenaline inhibits insulin secretion—ADCY5—osteoporosis	0.000283	0.0141	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—ESR2—osteoporosis	0.000274	0.0136	CbGpPWpGaD
Methyldopa—Diarrhoea—Estradiol—osteoporosis	0.000271	0.000974	CcSEcCtD
Methyldopa—DDC—Amino acid and derivative metabolism—PSMA5—osteoporosis	0.000264	0.0131	CbGpPWpGaD
Methyldopa—DDC—Amino acid and derivative metabolism—PSMA2—osteoporosis	0.000264	0.0131	CbGpPWpGaD
Methyldopa—Dizziness—Estradiol—osteoporosis	0.000262	0.000941	CcSEcCtD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—WDR1—osteoporosis	0.000252	0.0125	CbGpPWpGaD
Methyldopa—Vomiting—Estradiol—osteoporosis	0.000252	0.000905	CcSEcCtD
Methyldopa—Rash—Estradiol—osteoporosis	0.00025	0.000897	CcSEcCtD
Methyldopa—Dermatitis—Estradiol—osteoporosis	0.000249	0.000896	CcSEcCtD
Methyldopa—Headache—Estradiol—osteoporosis	0.000248	0.000892	CcSEcCtD
Methyldopa—ADRA2A—Regulation of insulin secretion—RAP1A—osteoporosis	0.000239	0.0119	CbGpPWpGaD
Methyldopa—Nausea—Estradiol—osteoporosis	0.000235	0.000845	CcSEcCtD
Methyldopa—COMT—Biological oxidations—CYP19A1—osteoporosis	0.000204	0.0101	CbGpPWpGaD
Methyldopa—COMT—Metapathway biotransformation—CYP19A1—osteoporosis	0.000201	0.01	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—CAP1—osteoporosis	0.000199	0.00989	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (z) signalling events—ADCY5—osteoporosis	0.000194	0.00963	CbGpPWpGaD
Methyldopa—ADRA2A—Integration of energy metabolism—RAP1A—osteoporosis	0.000188	0.00933	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—MGLL—osteoporosis	0.000158	0.00786	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—ADCY5—osteoporosis	0.000148	0.00735	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL6R—osteoporosis	0.000146	0.00724	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PLEK—osteoporosis	0.000145	0.00719	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—LEP—osteoporosis	0.000142	0.00706	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000132	0.00656	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PKM—osteoporosis	0.00013	0.00648	CbGpPWpGaD
Methyldopa—DDC—Metabolism—FDPS—osteoporosis	0.00013	0.00648	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—WDR1—osteoporosis	0.00013	0.00645	CbGpPWpGaD
Methyldopa—ADRA2A—Regulation of insulin secretion—ADCY5—osteoporosis	0.000126	0.00627	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TLN1—osteoporosis	0.000125	0.00619	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GPD2—osteoporosis	0.000124	0.00614	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PGLS—osteoporosis	0.000124	0.00614	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VCL—osteoporosis	0.000123	0.00611	CbGpPWpGaD
Methyldopa—COMT—Biological oxidations—POMC—osteoporosis	0.000123	0.0061	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PKM—osteoporosis	0.000116	0.00575	CbGpPWpGaD
Methyldopa—COMT—Metabolism—FDPS—osteoporosis	0.000116	0.00575	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CALCR—osteoporosis	0.000115	0.0057	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTH1R—osteoporosis	0.000115	0.0057	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—ADCY5—osteoporosis	0.000113	0.00563	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ATIC—osteoporosis	0.000113	0.00562	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PNP—osteoporosis	0.000113	0.00562	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL1B—osteoporosis	0.000111	0.00551	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PGLS—osteoporosis	0.00011	0.00545	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GPD2—osteoporosis	0.00011	0.00545	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—RAP1A—osteoporosis	0.000103	0.00511	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CAP1—osteoporosis	0.000103	0.0051	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PNP—osteoporosis	0.0001	0.00499	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ATIC—osteoporosis	0.0001	0.00499	CbGpPWpGaD
Methyldopa—ADRA2A—Integration of energy metabolism—ADCY5—osteoporosis	9.92e-05	0.00493	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CNR2—osteoporosis	9.71e-05	0.00482	CbGpPWpGaD
Methyldopa—DDC—Metabolism—OXCT1—osteoporosis	9.61e-05	0.00478	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CA2—osteoporosis	9.61e-05	0.00478	CbGpPWpGaD
Methyldopa—DDC—Metabolism—MGLL—osteoporosis	9.37e-05	0.00465	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—FGA—osteoporosis	9.32e-05	0.00463	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CNR2—osteoporosis	9.01e-05	0.00447	CbGpPWpGaD
Methyldopa—COMT—Metabolism—OXCT1—osteoporosis	8.54e-05	0.00424	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CA2—osteoporosis	8.54e-05	0.00424	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—FGB—osteoporosis	8.48e-05	0.00421	CbGpPWpGaD
Methyldopa—COMT—Metabolism—MGLL—osteoporosis	8.32e-05	0.00413	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MGLL—osteoporosis	8.15e-05	0.00405	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—TNF—osteoporosis	8.05e-05	0.004	CbGpPWpGaD
Methyldopa—DDC—Metabolism—IDH2—osteoporosis	7.97e-05	0.00396	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CNR2—osteoporosis	7.72e-05	0.00383	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP27A1—osteoporosis	7.49e-05	0.00372	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ANXA2—osteoporosis	7.46e-05	0.0037	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PLEK—osteoporosis	7.46e-05	0.0037	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ACP5—osteoporosis	7.29e-05	0.00362	CbGpPWpGaD
Methyldopa—COMT—Metabolism—IDH2—osteoporosis	7.07e-05	0.00351	CbGpPWpGaD
Methyldopa—DDC—Metabolism—TPI1—osteoporosis	6.77e-05	0.00336	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP27A1—osteoporosis	6.65e-05	0.0033	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL6—osteoporosis	6.5e-05	0.00323	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CALCR—osteoporosis	6.49e-05	0.00322	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PTH1R—osteoporosis	6.49e-05	0.00322	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ACP5—osteoporosis	6.47e-05	0.00321	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TLN1—osteoporosis	6.43e-05	0.00319	CbGpPWpGaD
Methyldopa—DDC—Metabolism—P4HB—osteoporosis	6.37e-05	0.00316	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VCL—osteoporosis	6.34e-05	0.00315	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GAPDH—osteoporosis	6.25e-05	0.00311	CbGpPWpGaD
Methyldopa—DDC—Metabolism—RAP1A—osteoporosis	6.09e-05	0.00302	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTH—osteoporosis	6.03e-05	0.003	CbGpPWpGaD
Methyldopa—COMT—Metabolism—TPI1—osteoporosis	6.01e-05	0.00299	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTH1R—osteoporosis	5.89e-05	0.00293	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CALCR—osteoporosis	5.89e-05	0.00293	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CNR2—osteoporosis	5.88e-05	0.00292	CbGpPWpGaD
Methyldopa—COMT—Metabolism—P4HB—osteoporosis	5.66e-05	0.00281	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GAPDH—osteoporosis	5.55e-05	0.00276	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—WNT1—osteoporosis	5.53e-05	0.00274	CbGpPWpGaD
Methyldopa—COMT—Metabolism—RAP1A—osteoporosis	5.41e-05	0.00269	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—IL6—osteoporosis	5.3e-05	0.00263	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RAP1A—osteoporosis	5.3e-05	0.00263	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—ADCY5—osteoporosis	5.17e-05	0.00257	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—MGLL—osteoporosis	5.15e-05	0.00256	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—PTHLH—osteoporosis	5e-05	0.00248	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—ADCY5—osteoporosis	4.95e-05	0.00246	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ENO1—osteoporosis	4.92e-05	0.00244	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PSMA2—osteoporosis	4.85e-05	0.00241	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PSMA5—osteoporosis	4.85e-05	0.00241	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—FGA—osteoporosis	4.81e-05	0.00239	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MGLL—osteoporosis	4.68e-05	0.00232	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PKM—osteoporosis	4.6e-05	0.00229	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—FDPS—osteoporosis	4.6e-05	0.00229	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CALCA—osteoporosis	4.4e-05	0.00219	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—FGB—osteoporosis	4.37e-05	0.00217	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ENO1—osteoporosis	4.37e-05	0.00217	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPD2—osteoporosis	4.36e-05	0.00217	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PGLS—osteoporosis	4.36e-05	0.00217	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PSMA2—osteoporosis	4.31e-05	0.00214	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PSMA5—osteoporosis	4.31e-05	0.00214	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PNP—osteoporosis	3.99e-05	0.00198	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ATIC—osteoporosis	3.99e-05	0.00198	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP19A1—osteoporosis	3.93e-05	0.00195	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SOST—osteoporosis	3.85e-05	0.00191	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IGF1—osteoporosis	3.84e-05	0.00191	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—POMC—osteoporosis	3.8e-05	0.00189	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP19A1—osteoporosis	3.49e-05	0.00174	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTH1R—osteoporosis	3.48e-05	0.00173	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALCR—osteoporosis	3.48e-05	0.00173	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PTH—osteoporosis	3.41e-05	0.00169	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CA2—osteoporosis	3.39e-05	0.00169	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—OXCT1—osteoporosis	3.39e-05	0.00169	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CNR2—osteoporosis	3.32e-05	0.00165	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MGLL—osteoporosis	3.31e-05	0.00164	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ADCY5—osteoporosis	3.22e-05	0.0016	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GPX1—osteoporosis	3.2e-05	0.00159	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTH—osteoporosis	3.09e-05	0.00154	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—osteoporosis	3.02e-05	0.0015	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CNR2—osteoporosis	3.02e-05	0.0015	CbGpPWpGaD
Methyldopa—DDC—Metabolism—MTHFR—osteoporosis	2.96e-05	0.00147	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ADCY5—osteoporosis	2.85e-05	0.00142	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GPX1—osteoporosis	2.84e-05	0.00141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—WNT1—osteoporosis	2.84e-05	0.00141	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PTHLH—osteoporosis	2.82e-05	0.0014	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—IDH2—osteoporosis	2.81e-05	0.0014	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MGLL—osteoporosis	2.76e-05	0.00137	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LRP5—osteoporosis	2.7e-05	0.00134	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP27A1—osteoporosis	2.64e-05	0.00131	CbGpPWpGaD
Methyldopa—COMT—Metabolism—MTHFR—osteoporosis	2.63e-05	0.0013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LRP6—osteoporosis	2.58e-05	0.00128	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ACP5—osteoporosis	2.57e-05	0.00128	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTHLH—osteoporosis	2.56e-05	0.00127	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CALCA—osteoporosis	2.49e-05	0.00123	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TPI1—osteoporosis	2.39e-05	0.00119	CbGpPWpGaD
Methyldopa—DDC—Metabolism—POMC—osteoporosis	2.36e-05	0.00117	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	2.3e-05	0.00114	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—POMC—osteoporosis	2.3e-05	0.00114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CALCA—osteoporosis	2.26e-05	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—P4HB—osteoporosis	2.25e-05	0.00112	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GAPDH—osteoporosis	2.21e-05	0.0011	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TLN1—osteoporosis	2.18e-05	0.00108	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—RAP1A—osteoporosis	2.15e-05	0.00107	CbGpPWpGaD
Methyldopa—COMT—Metabolism—POMC—osteoporosis	2.1e-05	0.00104	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IGF1—osteoporosis	1.98e-05	0.000983	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—P4HB—osteoporosis	1.88e-05	0.000933	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTH—osteoporosis	1.83e-05	0.000908	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAP1A—osteoporosis	1.8e-05	0.000892	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR2—osteoporosis	1.78e-05	0.000885	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADCY5—osteoporosis	1.77e-05	0.000878	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NFATC1—osteoporosis	1.75e-05	0.000871	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DKK1—osteoporosis	1.74e-05	0.000864	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO1—osteoporosis	1.74e-05	0.000863	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PSMA2—osteoporosis	1.71e-05	0.00085	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PSMA5—osteoporosis	1.71e-05	0.00085	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—WNT1—osteoporosis	1.68e-05	0.000832	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGA—osteoporosis	1.63e-05	0.000809	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADCY5—osteoporosis	1.61e-05	0.000798	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTHLH—osteoporosis	1.51e-05	0.000752	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BMP2—osteoporosis	1.51e-05	0.000752	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGB—osteoporosis	1.48e-05	0.000736	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PSMA2—osteoporosis	1.43e-05	0.000711	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PSMA5—osteoporosis	1.43e-05	0.000711	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP19A1—osteoporosis	1.39e-05	0.00069	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALCA—osteoporosis	1.33e-05	0.000662	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—POMC—osteoporosis	1.3e-05	0.000646	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KL—osteoporosis	1.21e-05	0.000601	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—osteoporosis	1.19e-05	0.00059	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—POMC—osteoporosis	1.18e-05	0.000587	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6R—osteoporosis	1.15e-05	0.000572	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADCY5—osteoporosis	1.13e-05	0.000563	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—osteoporosis	1.13e-05	0.000562	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—osteoporosis	1.04e-05	0.000518	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADCY5—osteoporosis	9.49e-06	0.000471	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPP1—osteoporosis	9.18e-06	0.000456	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—POMC—osteoporosis	8.34e-06	0.000414	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IRS2—osteoporosis	8.3e-06	0.000412	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEP—osteoporosis	8.12e-06	0.000403	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ESR1—osteoporosis	7.75e-06	0.000385	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IRS1—osteoporosis	7.25e-06	0.00036	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—POMC—osteoporosis	6.98e-06	0.000347	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6R—osteoporosis	6.81e-06	0.000338	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—osteoporosis	6.71e-06	0.000333	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—osteoporosis	5.13e-06	0.000255	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—osteoporosis	4.03e-06	0.0002	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—osteoporosis	4.02e-06	0.0002	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—osteoporosis	3.03e-06	0.000151	CbGpPWpGaD
